Amikacin liposomal - Gilead Sciences

Drug Profile

Amikacin liposomal - Gilead Sciences

Alternative Names: MiKasome

Latest Information Update: 09 Oct 2000

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Mycobacterium avium complex infections; Nosocomial infections; Pseudomonal infections; Tuberculosis; Urinary tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Oct 2000 Discontinued-I for Mycobacterium avium complex infections in USA (Parenteral)
  • 09 Oct 2000 Discontinued-I for Tuberculosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top